Osteoarthritis Treatment Market Shows Expected Growth from 2018-2026

Osteoarthritis Treatment Market: Worldwide Top
Players Revenue and Forecasts To 2026
Osteoarthritis Treatment Market - Global Industry Insights, Trends, Outlook, and
Opportunity Analysis, 2018-2026
Osteoarthritis also known as degenerative arthritis is the most commonly occurred chronic condition
that affects joints, especially those in the knees, neck, and lower back. Osteoarthritis leads to severe
joint pain and stiffness of the affected body part. These symptoms may occur in the initial stages
following some physical exercise, however, persists long after the activity. Several other symptoms of
osteoarthritis include decreased range of motion, joint swelling as well as numbness of the legs and
arms. This numbness is mostly found in the end joints of the fingers, neck, and lower back as well as
base of the thumb, hips, and knees. The progression of osteoarthritis results in movement patterns and
can ultimately result in joint effusion, usually in the knees. Osteoarthritis can be treated by several
treatments, which include exercise for reducing joint pain, pain medications, and support groups. Pain
medication includes drugs such as paracetamol, naproxen, and ibuprofen. Joint replacement is opted in
cases of severe pain that results in interference with the regular activities. Click To Read More On
Osteoarthritis Treatment Market.
Osteoarthritis as one of the most prevalent chronic diseases across the globe
Centers for Disease Control and Prevention, 2016, reveals that there are over 100 types of arthritis and
the most common form is osteoarthritis. Arthritis affected around 54.4 million adults in the U.S. during
2013- 2015. According to the Arthritis Foundation, 2014, over US$ 156 billion are dedicated annually
in lost wages and medical expenses towards treatment of arthritis. Moreover, Barbour 2017 states that
arthritis affects 1 in every 4 adults in U.S. The Arthritis Foundation also reveals that out of the 54.4
million arthritic patients in the U.S., around 30.8 million suffered from osteoarthritis, in 2015. These
key stats provide direct growth opportunities to the key players involved in the global osteoarthritis
treatment market.
Asian countries involved in innovation of novel therapies and drugs for treatment of
osteoarthritis
Based on the regional segmentation, the global osteoarthritis treatment market is segmented into North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds the
largest share of the global osteoarthritis treatment market, owing to the high prevalence rate of arthritis
in the region. The growing obese population in this region is also responsible for accelerating demand
for the osteoarthritis treatment, in turn boosting the market growth. Europe holds the second largest
share of market after North America, owing to expansion of healthcare budget to many folds and
significant outcomes of the R&D sector.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/915
The key players are focusing on R&D to establish their presence in the global osteoarthritis
treatment market
The key players operating the global osteoarthritis market are Johnson & Johnson Ltd., Abbott
Laboratories, Pfizer, Inc., Novartis AG, Eli Lily and Co., Abiogen Pharma, Ampio Pharmaceuticals,
Halyard Health, and BioDelivery Sciences International, Inc. The companies are involved in
introducing new and innovative products for the osteoarthritis treatment to increase sales in the global
market. For instance, the Halyard Health introduced the first cooled radiofrequency (RF), minimally
invasive needles, and water cooled electrodes that are specifically used to alleviate chronic knee pain in
osteoarthritis.
Cost-effective and innovative medications responsible to drive the global osteoarthritis treatment
market
The emergence of new and cost effective medications for the treatment of osteoarthritis is the major
growth driver of the global osteoarthritis treatment market. The Tanezumab, a drug jointly developed
by Pfizer and Eli Lily, 2017, used for the chronic lower back pain relief in osteoarthritis, is awaiting
FDA approval, which is expected to help millions of people. Obesity, increasing number of orthopedic
injuries, crystal deposition, old age, joint injury, increasing number of pipeline drugs, and rising
awareness among people are few other factors responsible for driving growth of the global
osteoarthritis treatment market.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]

Osteoarthritis also known as degenerative arthritis is the most commonly occurred chronic condition that affects joints, especially those in the knees, neck, and lower back. Osteoarthritis leads to severe joint pain and stiffness of the affected body part.